Neurotoxicity is the side effect to look out for with administration of CAR T-cell therapy. So much so that the risk necessitates inpatient observation. In this retrospective review of 204 patients treated with CAR T-cells within the Harvard health system, 58% of whom developed some degree of neurotoxicity, an effective predictive risk model was developed based on labs like CRP, ferritin, and WBC, as well as patient age, temp and history of cytokine release syndrome and/or need for tocilizumab. TBL: A new predictive model offers a sensitivity of 82% for subsequent neurotoxicity with CAR T-cells, hopefully offering an opportunity for some patients to be safely discharged sooner after therapy. | Rubin, JAMA Neurol 2020


Popular Posts